HSP

KUNB31 is a selective inhibitor of HSP90β, exhibiting a binding affinity with a Kd value of 0.18 μM. This compound disrupts the function of the HSP90β protein, which is implicated in the maturation and stabilization of client proteins involved in cancer and other diseases. KUNB31 is valuable for research focused on cellular stress responses, protein homeostasis, and therapeutic strategies targeting protein chaperones.

Hsp90-IN-37 is a potent inhibitor of heat shock protein 90 (Hsp90), demonstrating a 69% reduction in enzymatic activity. This compound exhibits significant antitumor properties, making it a valuable tool in cancer research. Hsp90-IN-37 can be utilized to explore the role of Hsp90 in cancer cell survival and proliferation, supporting efforts to develop targeted therapies.

3-Phenyltoxoflavin is an Hsp90 inhibitor that interacts with the Hsp90-TPR2A complex, exhibiting a dissociation constant (Kd) of 585 nM. This compound demonstrates significant anti-cancer properties, making it a valuable tool for cancer research. Its ability to inhibit Hsp90 function provides insights into the molecular mechanisms of cancer cell growth and survival, supporting studies aimed at developing targeted therapies.

Hsp90-IN-17 hydrochloride is a potent inhibitor of Heat Shock Protein 90 (HSP90), a chaperone protein involved in protein folding and stabilization. This compound demonstrates significant biological activity by disrupting the chaperoning function of HSP90, leading to the degradation of oncogenic client proteins. Hsp90-IN-17 is primarily used in research applications focused on proliferative diseases, including various cancer types and neurodegenerative disorders, providing insights into therapeutic strategies targeting HSP90.

HSP90-IN-23 is a potent inhibitor of heat shock protein 90 (HSP90) with an IC50 value of 9 nM. This compound effectively induces apoptosis in tumor cells and successfully arrests the cell cycle in the G0/G1 phase. HSP90-IN-23 is an invaluable tool for cancer research, facilitating the study of HSP90's role in tumorigenesis and potential therapeutic strategies.

AP-4-139B is a potent inhibitor of HSP70, exhibiting an IC50 of 180 nM against human HSP70. Its mechanism involves direct binding to HSP70, leading to the inhibition of ATPase activity. By facilitating the phosphorylation of Beclin-1, AP-4-139B promotes autophagy. This compound has demonstrated significant antitumor activity in preclinical models of colorectal cancer and pancreatic ductal adenocarcinoma, making it a valuable tool for cancer research.

HSP90-IN-22 is an inhibitor of heat shock protein 90 (Hsp90) that exhibits significant antiproliferative activity in cancer cells. The compound demonstrates IC50 values of 3.65 μM in MCF7 breast cancer cells and 2.71 μM in SKBr3 breast cancer cells. This compound is valuable for research into cancer cell biology and the therapeutic potential of Hsp90 inhibition in cancer treatment.

HS-27 is a fluorescently-tethered inhibitor targeting Heat Shock Protein 90 (Hsp90), facilitating the assessment of surface Hsp90 expression on intact tissue specimens. Comprising core elements of SNX-5422 linked through a PEG spacer to a fluorescein derivative, HS-27 selectively binds to ectopically expressed Hsp90. This reagent is particularly valuable in breast cancer research, providing a tool for applications involving visualization and treatment strategies.

Apatorsen is a 2'-methoxyethyl-modified antisense oligonucleotide that functions as a Heat Shock Protein 27 (Hsp27) inhibitor. By reducing Hsp27 mRNA and protein levels, Apatorsen disrupts stress-induced cytoprotective mechanisms, promotes apoptosis, inhibits tumor growth, and prevents metastasis. This compound is particularly relevant for research focused on non-small cell lung cancer, castration-resistant prostate cancer, breast cancer, ovarian cancer, and bladder cancer.

Aminohexylgeldanamycin (AHGDM) is a potent inhibitor of HSP90, a chaperone protein essential for the proper folding and function of many oncoproteins. This compound exhibits significant antiangiogenic and antitumor activities, making it a valuable tool in cancer research. Its ability to disrupt HSP90 function highlights its potential in the study of tumor biology and therapeutic interventions targeting heat shock proteins.

CH5015765 is a potent HSP90 inhibitor that targets the N-terminal ATP binding site with a dissociation constant of 3.4 nM. This compound demonstrates significant antiproliferative activity, exhibiting IC50 values of 0.46 μM in HCT116 colorectal cancer cells and 0.57 μM in NCI-N87 gastric cancer cells. CH5015765 is suitable for research applications focused on cancer biology and therapeutic development.

HSP90-IN-27 is a potent inhibitor of the heat shock protein 90 (HSP90), which plays a critical role in protein folding and stabilization of client proteins involved in cancer progression. This compound effectively disrupts HSP90 function, leading to the degradation of oncogenic proteins and subsequent inhibition of tumor growth. HSP90-IN-27 is applicable in cancer research, particularly in studies focused on targeted therapies and the molecular chaperone network.

[Au(TPP)]Cl is an inhibitor of the Hsp60-Hsp10 complex, which plays a critical role in protein folding and cellular stress responses. This compound demonstrates significant anticancer activity by disrupting the refolding process of misfolded proteins, thereby promoting cell apoptosis in cancerous cells. [Au(TPP)]Cl is valuable for research applications targeting cancer therapy and understanding the molecular mechanisms of chaperone functions.

Onalespib lactate is a highly potent inhibitor of heat shock protein 90 (Hsp90) with a Kd of 0.71 nM, demonstrating the capability to cross the blood-brain barrier. This compound effectively inhibits tumor cell proliferation, survival, and migration, while reducing the expression of key signaling proteins such as EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, and P-S6. With its significant antitumor activity, Onalespib lactate is particularly relevant for research into non-small cell lung cancer (NSCLC).

HSP90-IN-11 is a potent inhibitor of HSP90, exhibiting strong inhibition of HSP90α activity. This compound demonstrates significant antiproliferative effects in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) cell lines, with IC50 values in the low double-digit nanomolar range. HSP90-IN-11 facilitates the rapid degradation of client proteins such as EGFR and Akt in NSCLC cells and induces a notable accumulation of sub-G1 phase cell populations, highlighting its potential for cancer research applications.

BX-2819 is a potent inhibitor of Heat Shock Protein 90 (Hsp90) with an IC50 value of 41 nM. This compound effectively inhibits the proliferation of various cancer cell lines and has demonstrated significant antitumor activity in vivo, notably reducing the growth of NCI-N87 and HT-29 tumors in nude mouse models. BX-2819 is a valuable tool for research into cancer biology and potential therapeutic strategies targeting Hsp90.

CH5164840 is a potent inhibitor of the N-terminal domain of Hsp90a, exhibiting a high binding affinity with a Kd value of 0.52 nM. This compound demonstrates significant anti-proliferative effects against various human cancer cell lines, including HCT116 and NCI-N87, with IC50 values of 0.15 μM and 0.066 μM, respectively. Additionally, CH5164840 has an oral bioavailability profile with a half-life of 2.64 hours, indicating its potential for effective antitumor applications in therapeutic settings.

HSP90-IN-19 is a potent inhibitor of heat shock protein 90 (Hsp90), identified for its effective inhibitory activity with an IC50 value of 0.27 μM. This compound is relevant for studies investigating viral infections, neurodegenerative diseases, and inflammatory processes. Its ability to modulate cellular stress response pathways makes it a valuable tool in biochemical research and drug development efforts targeting Hsp90.

Hsp90-IN-47 is a potent Hsp90 inhibitor, demonstrating an IC50 of 0.014 μM against Hsp90α. This compound exhibits significant antifungal properties, particularly when used in combination with Fluconazole, enhancing efficacy against fluconazole-resistant strains of Candida albicans. Additionally, Hsp90-IN-47 shows promising antitumor activity, particularly in acute myeloid leukemia and non-small cell lung cancer research applications.